Characteristics of COPD Phenotypes in Serbia

References

• Heffler E, Paoletti G, Giorgis V, et al. Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol. 2019;15(9):951–958. doi:10.1080/1744666X.2019.1653758
   PubMed Web of Science ®Google Scholar
• Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The norwegian patient registry and the norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55. doi:10.1177/1403494819859737
   PubMed Web of Science ®Google Scholar
• Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20(3):548–556. doi:10.1002/ejhf.1045
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
   PubMed Web of Science ®Google Scholar
• Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-0655
   PubMed Web of Science ®Google Scholar
• Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35(1):1–6. doi:10.1016/j.ccm.2013.10.010
   PubMed Web of Science ®Google Scholar
• Guerreiro I, Soccal PM. COPD and phenotypes. Rev Med Suisse. 2019;15(671):2082–2086.
   PubMedGoogle Scholar
• Siafakas N, Corlateanu A, Fouka E. Phenotyping Before Starting Treatment in COPD? COPD. 2017;14(3):367–374. doi:10.1080/15412555.2017.1303041
   PubMedGoogle Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirol Carlton Vic. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3–12. doi:10.2147/COPD.S85976
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.580
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018
   PubMed Web of Science ®Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. doi:10.1183/13993003.01446-2016
   PubMed Web of Science ®Google Scholar
• Reiger G, Zwick R, Lamprecht B, Kähler C, Burghuber OC, Valipour A. Phenotypes of COPD in an Austrian population: national data from the POPE study. Wien Klin Wochenschr. 2018;130(11–12):382–389. doi:10.1007/s00508-018-1347-7
   PubMed Web of Science ®Google Scholar
• Alcázar-Navarrete B, Trigueros JA, Riesco JA, Campuzano A, Pérez J. Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study.”. Int J Chron Obstruct Pulmon Dis. 2018;13:1115–1124. doi:10.2147/COPD.S158031
   PubMed Web of Science ®Google Scholar
• Riesco JA, Alcázar B, Trigueros JA, Campuzano A, Pérez J, Lorenzo JL. Active smoking and COPD phenotype: distribution and impact on prognostic factors. Int J Chron Obstruct Pulmon Dis. 2017;12:1989–1999. doi:10.2147/COPD.S135344
   PubMed Web of Science ®Google Scholar
• Mejza F, Nastałek P, Mastalerz-Migas A, Doniec Z, Skucha W. Coexistence of chronic bronchitis in chronic obstructive lung disease. Adv Exp Med Biol. 2018;1114:1–9.
   PubMed Web of Science ®Google Scholar
• Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Med Clin North Am. 2019;103(3):453–461. doi:10.1016/j.mcna.2018.12.005
   PubMed Web of Science ®Google Scholar
• Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255–3262. doi:10.2147/COPD.S142997
   PubMed Web of Science ®Google Scholar
• Chai C-S, Liam C-K, Pang Y-K, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2019;14:565–573. doi:10.2147/COPD.S196109
   PubMed Web of Science ®Google Scholar
• Kania A, Krenke R, Kuziemski K, et al. Distribution and characteristics of COPD phenotypes – results from the Polish sub-cohort of the POPE study. Int J Chron Obstruct Pulmon Dis. 2018;13:1613–1621. doi:10.2147/COPD.S154716
   PubMed Web of Science ®Google Scholar
• Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev off J Eur Respir Soc. 2009;18(114):213–221. doi:10.1183/09059180.00003609
   PubMedGoogle Scholar
• André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology. 2019;25(3):168–176. doi:10.1016/j.pulmoe.2018.09.006
   PubMed Web of Science ®Google Scholar
• Leitao Filho FS, Sin DD. COPD and cardiovascular diseases: now is the time for action! Thorax. 2018;73(9):799–800. doi:10.1136/thoraxjnl-2018-211553
   PubMed Web of Science ®Google Scholar
• Zhou A, Zhou Z, Zhao Y, Chen P. The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1009–1018. doi:10.2147/COPD.S128604
   PubMed Web of Science ®Google Scholar
• Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462. doi:10.2147/COPD.S157779
   PubMed Web of Science ®Google Scholar
• Brown KE, Johnson KJ, DeRonne BM, Parenti CM, Rice KL. Order set to improve the care of patients hospitalized for an exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(6):811–815. doi:10.1513/AnnalsATS.201507-466OC
   PubMed Web of Science ®Google Scholar